Carbohydrate-lectin interactions intervene in and mediate most biological processes, including ac rucial modulation of immune responsest op athogens. Despite growing interesti n investigating the association between host receptorl ectins and exogenous glycanl igands, the molecular mechanisms underlying bacterial recognition by human lectins are still not fully understood.H erein, an ovel molecular interaction between the human macrophage galactose-type lectin (MGL) and the lipooligosaccharide (LOS) of Escherichia coli strain R1 is described. Saturation transfer difference NMR spectroscopy analysis, supportedb yc omputational studies, demonstrated that MGL bound to the purified deacylated LOS R1 mainly throughr ecognition of its outer core and established crucial interactions with the terminal Gala(1,2)Gal epitope. These results assess the ability of MGL to recognise glycan moieties exposed on Gram-negative bacterial surfaces.Bacterialc ell surfaces are decorated with highly diverseg lycoconjugates,i nt he form of capsular polysaccharides, peptidoglycans, lipopolysaccharides( LPSs) and other glycolipids, [1] which perform severalf unctions, ranging from structural to protective roles. [2] Bacterial glycans take part in many keyb iological events, including pathogen recognition,receptor activation, cell adhesion and signal transduction. Additionally,t hese structures often serve as molecular patterns that are recognised by specific glycan-binding receptors of the host immune system,t hus triggeringapathogen-specific immune response.It is well known that LPSs, the major constituents of the outer membrane of Gram-negative bacteria, [3] are one of the main virulence factorsofseveral feared bacterialstrains,including enteropathogenic Escherichia coli,w hich is implicated in severe foodborne and urinary tract infections. [4] From as tructural point of view,L PS is composed of three structural motifs that can be distinguishedb ecause they are encoded by different gene clusters. Lipid A, which represents the glycolipid portion, is an acylated bis-phosphorylated glucosamined isaccharide that anchors the LPS to the outer membrane. Lipid Ai sc ovalentlyl inked to ac ore oligosaccharide (OS) that can be further divided into two different portions: the more conserved inner region, which is characterised by the presence of peculiar sugar residues,s uch as 3-deoxy-d-manno-oct-2-ulopyranosonic acid (KDO),a nd the more variableo uter core. Finally,t he O-antigen, which is ap olysaccharide composed of severalO S repeating units, extends to the extracellularm edium and acts as ah ydrophilic coating surface. [3,5] However,G ram-negative bacteria can also produce rough-typeL PS, namely,l ipooligosaccharide (LOS);atruncated version of LPS that lacks the Oantigen.To date, the receptor complex formed by the toll-like receptor 4a nd the small secreted MD2 protein is among the main speciesi nvolved in bacterial LPS recognition by host immune cells. [6] More recently,i th as been shown that LPSs are also intracellularly detected by caspases...
Alterations in glycosylation cause the emergence of tumor-associated carbohydrate antigens (TACAs) during tumorigenesis. Truncation of O-glycans reveals the Thomsen nouveau (Tn) antigen, an N-acetylgalactosamine (GalNAc) frequently attached to serine or threonine amino acids, that is accessible on the surface of cancer cells but not on healthy cells. Interestingly, GalNac can be recognized by macrophage galactose lectin (MGL), a type C lectin receptor expressed in immune cells. In this study, recombinant MGL fragments were tested in vitro for their cancer cell-targeting efficiency by flow cytometry and confocal microscopy and in vivo after administration of fluorescent MGL to tumor-bearing mice. Our results demonstrate the ability of MGL to target Tn-positive human tumors without inducing toxicity. This outcome makes MGL, a fragment of a normal human protein, the first vector candidate for in vivo diagnosis and imaging of human tumors and, possibly, for therapeutic applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.